Committee hears testimony that Medicare negotiation and drug caps can ease seniors’ costs; witnesses clash over industry influence

Multiple senators and witnesses at the Special Committee on Aging identified high prescription drug prices as a central driver of seniors’ cost burdens and discussed recent federal steps and possible expansions.

Alex Lawson highlighted the Inflation Reduction Act’s tools and said the law helps but can go further: lawmakers could expand negotiation authority to more drugs. “For decades, pharmaceutical corporations have been able to raise the prices year after year enormously above the rate of inflation,” Lawson testified, adding that high drug costs force some seniors to “cut their pills in half or forego their prescriptions.”

Witnesses pointed to specific provisions already enacted: the Inflation Reduction Act included limited Medicare negotiation authority and caps on certain out‑of‑pocket costs (witnesses noted the $35 insulin cap and broader annual limits that affect Medicare beneficiaries). Senator Chris Van Hollen and others described the direct effect on household budgets if premium tax credits or negotiated savings were reversed.

Committee discussion contrasted approaches: some senators and witnesses urged expanding government negotiation and stronger price caps; others emphasized market and supply measures as part of a broader fiscal strategy. The committee recorded no votes; members asked witnesses for additional evidence and said they will continue oversight of drug pricing and the implementation of negotiated price reductions.